iNtRON Biotechnology, Inc.
http://www.intron.co.kr
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From iNtRON Biotechnology, Inc.
Basilea Buoyant As Antibiotic Finally Gets US Nod
Sales of the Swiss firm’s Zevtera are set to rocket after the beta-lactam antibiotic got approval from the US Food and Drug Administration. Now Basilea needs to sign up a commercial partner.
Basilea Snaps Up Another Antibiotics Program As Pipeline Swells
The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Biotech Deals Stand Out In 2018 Korean Licensing Trends
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice